Remember the architect had noted that the share price could/should go to 6400. With the architect protecting himself and selling I'd call that a negative architect sign....the equivalent of three black crows technically and you didn't pick that up Yugo. Instead you lead your followers to an additional 30% loss after the initial decrease down from 101. t
Like the movie Dumb and Dumber, Mr. Beer would sell Pettie the parakeet who had is head pulled off to the blind kid. t
Jealousy??? You can't even see through him, Mr. Beer. If he was Sister Teresa he would have never raised the price of the med within less than a year. He raised it because of.....DEMAND and yet there is doubt whether or not the company can meet those predicted goals. The reality of the situation is that he saved that move to move the stock up and people bit on that worm. He NEVER said that he was going to not reveal individual data until things got rolling or NOT rolling and he wanted to buy time and hide out for a while. Just to listen to him in that last CC when the woman moderator was going to ask him a second question and he barges in with the pediatric "information" about their doing a study was hideous. First, he really was supposed to not really talk about anything off label according to his FDA hand slapping. Secondly, he initiated the pediatric "news." Thirdly, he said that the company wasn't talking about it because they only had the indication for adults........and yet HE brought up the subject, and HE talked about it. He went out on that limb because he is in trouble from his previous Chief Biggy-a-Biggy mouth statements about how many patients there really are out there. It is like a politician stating he isn't going to talk about his opponents affair...... and he just did. This guy is a friend only to JS and the analysts that are under his spell. Even you Yugo does not matter to him, and the DB analyst will have to live with that 115 target that allowed the real DB investors to get out of the collapsing building. The architect was able to get out but maybe that is because his is an architect and you drive a Yugo. t6
You could of at least bought some puts to protect your investment. Instead you are well....a Yugo. t
Yugo you are a dxxx. Got no balls? Can't you take it? Just pointing out truths as they are. Not jealous of the CEO, he is a fake and makes a person's stomach turn. Helping children???? Make sure you listen carefully when the person who gets fake tears in his eyes about nine months ago about lethal levels of lipids pulsating through these HoF patients bodies have to first get their insurance totally and completely finalized before a shipment of even the weakest strength of the med gets shipped to them. Your architect buddy sold off, or is telling people he sold off to save face quite a while ago. I told you about the problems of the company in the high 80's, because you are so stupid you lost out. Your architect buddy acted on his own volition but saved himself. Tell me again about how I'm going to criticize the situation in regards to stock options, and accuse me again of being an Obama lover and then within 24 hours accuse me again of being a KKK. Then tell everyone about how the stock should go to 6400. You really have it all together. t
and by "dredge up" you mean marketing?
Whatever. So if you hate the company so bad, why do you pretend to be long?
Just admit you are AdamWang/Censored/DikhedMorOn and be done with it.
What are you so afraid of? Got no balls?
Why are you so incredibly jealous of his (CEOs) success?
Why are you so incredibly against them helping children?
What kind of horrible person are you?
The other thing that Yugo isn't talking about is the very big possibility of a shelf offering to allow Mr. Beer to reach his goals of expanding quickly with no real earnings coming in for the foreseeable future. Look for another 25 million shares to come on board so he can try and meet his goals. t
The real issue, not the reimbursement issue like Yugo wants to keep talking about is cash flow in vs. Mr. Beer's lofty goals of trying to dredge up more people to take the drug. He is going to keep on studying "the issue" and he is going to "study" the pediatric issue all the while trying to set up a pediatric trial and expand his COMPASS group while the company is losing money and time. He did an anctedotal study of other CEO's and he claims they told him that they regretted expanding faster and thus based on that "wisdom" he goes forth. He elevated investors expectations and he actually sicced the FDA on himself. He is a total mess and his perceptions and sense of responsibility are totally off. The DB analyst who recommended the 115 target is the same person who interviewed him for that last Dec3rd interview. The one where he brought up the pediatric population first and then said "we at AEGR" don't talk about it........ But HE DID. t
I think number the way the disease is going to be defined....phenotypically is going to be higher than one in a million. However, if the modern surveying of the population is really exact then why does Mr. Beer want to keep on studying it? The architect who said the stock could go to 6400 has confessed he is out of it......to weight for a better price? The 6400 concept is a fool's error. t
It is the difference between theory and practice. The jokers that pretend the 1-in-a-million number is right still won't acknowledge that the number is based on studies going back to 1970 and even the summary Wiki article is 2002.
AEGRs numbers are real world patients based on doctors diagnosis (not AEGR's diagnosis, it was the patients doctors who diagnosed them).
Now lets argue about how nobody has insurance (even though 100% of the people have it covered by insurance right now).
ISIS Kynamro is no competitor and is old news. The news is outdated and the drug doesn't work. It has already been proven. This one isn't even worth arguing about. Go back to arguing how there are only 300 patients in the US instead of 3,000.
There is no such thing as an unbiased view, but everybody will give you their opinion nonetheless. The stock is going down because of a perceived change in the fundamentals. The next quarterly results will set the tone going forward. The main change is that initially the company gave specifics on how many patients were on treatment and now they no longer do that (they cautioned from the beginning that they would only do that in the beginning, so it was pre-planned & pre-announced that way - but it was still a change in the granularity of the information released). So people are uncertain as to the true growth in revenues.
There is one guy here who lost his life savings shorting the stock who keeps whining about how there is only 1 in a million cases of HoFH but that is statistically speaking and based on grossly outdated information (well discredited long ago). The number of patients diagnosed with HoFH is what AEGR is using as their baseline number of 15,000 worldwide and 3,000 in the USA. However, it doesn't mean that all of them will buy the medication. Despite what the one short-loser harps on, who pretends nobody can afford it, people DO have insurance and it IS covering it, so the real question is to see how that pans out for the longer term.
If you watch the options numbers there is a very strong speculation that next quarters numbers will be very high, but that easily could be people who sold the stock and bought the option to minimize their downside while still keeping open the upside. Downward pressure is also coming from those (like me) who took profits to lock them in before year end. Nothing particularly wrong with the company or stock but there is substantial uncertainty in the overall market and that warrants prudent steps which includes locking in stellar profits. I'm one of those who locked in profits and will be buying more shortly, though I want to see the new numbers next quarter. I want to see the growth continue.
Doing your own DD is far superior to following sell-side analysts. Reading the 10-K at the SEC is a must.
Read the disclosures on analysts reports and see who is paying them. Also go to brokercheck at finra org and look up the institution behind the report. Look for regulatory events for Deutsche Bank Securities.
Yeah: Nov. 13, 2013 "Deutsche Bank maintained a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) and raised its price target to $115.00 (from $107.00). Analyst Robyn Karnauskas sees accelerating sales."
"Following the Aegerion analyst day and our recent channel checks we are increasing our 2014 sales estimates and raising our TP to $115," said Karnauskas. "Given more docs are prescribing and scripts from current docs are increasing, we expect sales to continue to accelerate."
stock flew up to the 80's then crashed back into the 60's.
brokercheck at finra org shows a history for Deutsche Bank Securities. Almost 200 regulatory events, many involving research reports.
Sentiment: Strong Sell
Some people thought that they would make their investment and just move to Mexico and the money would roll in like that movie Trading Places......get me another beer Louis. t
Just as an aside....who was that DB analyst who increased their target for AEGR to $110 and what was there time frame? And in reality what was their motive?? t
Mr. Beer has boxed himself in. He has the market expecting over 15,000 patients worldwide, and at least 3000 patients in the US. He is going to over promise and under produce. He is going after the pediatric population which will be at least THREE TIMES more costly than what he was able to pull of with the adult population in regards to that 29 patient single armed clinical study. He has made the FDA put a gag-order on him, and his stock greatly underperformed high beta stocks today in a market that should have been much better for AEGR. The best case scenario is for the stock to gradually fall to three times above the original offering price. The worst case scenario is for the stock to act like another AMRN. Mr. Beer should be replaced as he is a lame duck CEO IMO. The studying and re-studying of the adult eligible population most probably will not be paid for by the new discoveries in regards to new patients turned up by these repeated studies. And AEGR may not have the monetary resources to perform a full pediatric clinical workup to gain new patients. The FCS patients that they were hoping for have disappeared by new products from NVS and ISIS for which the company certainly will not be able to compete against based on their one patient on their MTP inhibitor for 16 years for that condition started on by the Harvard physician no less. They will need a full study that will cost another $70 million even to start to compete. This company is on the verge of insolvency IMO. t